Exhibit 10.2


 


SECURITY
AGREEMENT


 


SECURITY AGREEMENT dated as of May 15, 2015
among NAVIDEA PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), MACROPHAGE THERAPEUTICS, INC.,
a Delaware corporation (“Macrophage”; collectively with each entity that becomes a “Grantor”
hereunder as contemplated by Section 5.12, the “Grantors” and each, a “Grantor”),
CAPITAL ROYALTY PARTNERS II L.P., CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” L.P. and PARALLEL INVESTMENT
OPPORTUNITIES PARTNERS II L.P. (together, the “Lenders” and each, a “Lender”)
and CAPITAL ROYALTY PARTNERS II L.P., as control agent for the Secured Parties (in such capacity, the “Control Agent”
and, together with the Lenders, the “Secured Parties” and each, a “Secured Party”).


 


The Secured Parties have agreed to provide
term loans to Borrower as provided in the Loan Agreement (as defined below).


 


To induce the Secured Parties to extend
credit under the Loan Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, each Grantor has agreed to grant a security interest in the Collateral (as defined below) of such Grantor as security
for the Secured Obligations (as defined below).


 


Accordingly, the parties hereto agree as
follows:


 


Section 1.          Definitions,
Etc.


 


1.01    Certain
Uniform Commercial Code Terms. As used herein, the terms “Accession”, “Account”,
“As-Extracted Collateral”, “Chattel Paper”, “Check,”
“Commodity Account”, “Commodity Contract”, “Deposit Account”,
“Document”, “Electronic Chattel Paper”, “Encumbrance,”
“Equipment”, “Fixture”, “General Intangible”, “Goods”,
“Instrument”, “Inventory”, “Investment Property”,
“Letter-of -Credit Right”, “Proceeds,” “Promissory Note,”
“Record” and “Supporting Obligation” have the respective meanings set forth
in Article 9 of the NYUCC, and the terms “Certificated Security”, “Entitlement Holder”,
“Financial Asset”, “Securities Account”, “Security”,
“Security Entitlement” and “Uncertificated Security” have the respective meanings
set forth in Article 8 of the NYUCC.


 


1.02    Additional
Definitions. In addition, as used herein:


 


“Collateral” has
the meaning assigned to such term in Section 3.01.


 


“Control Agent”
has the meaning assigned to such term in the preamble.


 


“Controlled Foreign Corporation”
means a “controlled foreign corporation” as defined in the Code.


 


“Copyrights” means
all copyrights, copyright registrations and applications for copyright registrations, including all renewals and extensions thereof,
all rights to recover for past, present or future infringements thereof and all other rights whatsoever accruing thereunder or
pertaining thereto.


 




    	 



    	 



    

 


“Excluded Asset”
means, to the extent any property is excluded from the Collateral solely by operation of Section 3.02, such property.


 


“Initial Pledged Shares”
means the Shares of each Issuer beneficially owned by any Grantor on the date hereof and identified in Annex 2.


 


“Issuers” means,
collectively, (a) the respective Persons identified on Annex 2 under the caption “Issuer”, (b) any other Person
that shall at any time be a Subsidiary of any Grantor, and (c) the issuer of any equity securities hereafter owned by any Grantor.


 


“Joinder” has
the meaning specified in Section 5.12.


 


“Loan Agreement”
means that certain term loan agreement, dated as of the date hereof, among Borrower and the Secured Parties, as such agreement
is amended, supplemented, or otherwise modified, restated, extended, renewed, or replaced from time to time.


 


“Motor Vehicles”
means motor vehicles, tractors, trailers and other like property, if the title thereto is governed by a certificate of title or
ownership.


 


“NYUCC” means
the Uniform Commercial Code as in effect from time to time in the State of New York.


 


“Patents” means
all patents and patent applications, including the inventions and improvements described and claimed therein together with the
reissues, divisions, continuations, renewals, extensions and continuations in part thereof, all income, royalties, damages and
payments now or hereafter due and/or payable with respect thereto, all damages and payments for past or future infringements thereof
and rights to sue therefor, and all rights corresponding thereto throughout the world.


 


“Pledged Property”
means the Deposit Accounts, the Pledged Shares, the Securities Accounts, the Commodity Accounts and all or any part of any other
present or future interests of any Grantors in Investment Property, including all of the present or future Security Entitlements
of such Grantor as Entitlement Holders in respect of such Security Entitlements, all of the present or future Commodity Contracts
of such Grantor as commodity customers in respect of such Commodity Contracts, all credit balances relating to such property, all
Chattel Paper, Electronic Chattel Paper, Instruments and Letter-Of-Credit Rights of Grantors, and all other rights and benefits
accruing to or arising in connection with such property, and all Proceeds of such property.


 


“Pledged Shares”
means, collectively, (i) the Initial Pledged Shares and (ii) all other Shares of any Issuer now or hereafter owned by any Grantor,
together in each case with (a) all certificates representing the same, (b) all shares, securities, moneys or other property representing
a dividend on or a distribution or return of capital on or in respect of the Pledged Shares, or resulting from a split-up, revision,
reclassification or other like change of the Pledged Shares or otherwise received in exchange therefor, and any warrants, rights
or options issued to the holders of, or otherwise in respect of, the Pledged Shares, and (c) without prejudice to any provision
of any of the Loan Documents prohibiting any merger or consolidation by an Issuer, all Shares of any successor entity of any such
merger or consolidation.


 




    	2



    	 



    

 


“Secured Obligations”
means, with respect to each Grantor, the Obligations of such Grantor.


 


“Secured Parties”
means each of the Persons listed on the signature pages hereto as “Secured Party” and their successors and assigns
as Lenders under the Loan Agreement.


 


“Secured Parties Representative”
has the meaning specified in Section 4.05.


 


“Shares” means
shares of capital stock of a corporation, limited liability company interests, partnership interests and other ownership or equity
interests of any class in any Person.


 


“Trademarks” means
all trade names, trademarks and service marks, logos, trademark and service mark registrations, and applications for trademark
and service mark registrations, including all renewals of trademark and service mark registrations, all rights to recover for all
past, present and future infringements thereof and all rights to sue therefor, and all rights corresponding thereto throughout
the world, together, in each case, with the product lines and goodwill of the business connected with the use thereof.


 


1.03    Other
Defined Terms. All other capitalized terms used and not defined herein have the meanings ascribed to them in the Loan Agreement.


 


Section 2.          Representations
and Warranties. Each Grantor represents and warrants to the Secured Parties that:


 


2.01    Organizational
Matters; Enforceability, Etc. (a) Each Grantor is duly organized, validly existing and in good standing under the laws of the
jurisdiction of its organization. The execution, delivery and performance of this Agreement, and the grant of the security interests
pursuant hereto, (a) are within such Grantor’s powers and have been duly authorized by all necessary corporate or other action,
(b) do not require any consent or approval of, registration or filing with, or any other action by, any governmental authority
or court, except for (i) such as have been obtained or made and are in full force and effect and (ii) filings and recordings in
respect of the security interests created pursuant hereto, (c) will not violate any applicable law or regulation or the charter,
bylaws or other organizational documents of such Grantor or any order of any governmental authority or court binding upon such
Grantor or its property, (d) will not violate or result in a default under any indenture, agreement or other instrument binding
upon such Grantor or any of its assets, or give rise to a right thereunder to require any payment to be made by any such person,
and (e) except for the security interests created pursuant hereto, will not result in the creation or imposition of any Lien on
any asset of such Grantor.


 


(b)          This
Agreement has been duly executed and delivered by such Grantor and constitutes, a legal, valid and binding obligation of such Grantor,
enforceable against such Grantor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy,
insolvency, reorganization, moratorium or similar laws of general applicability affecting the enforcement of creditors’ rights
and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding
in equity or at law).


 




    	3



    	 



    

 


2.02    Title.
(a) Such Grantor is the sole beneficial owner of the Collateral in which it purports to grant a lien hereunder, and no lien exists
upon such Collateral (and no right or option to acquire the same exists in favor of any other Person) other than Permitted Liens.


 


(b)          The
security interest created or provided for herein constitutes a valid first-priority (subject to Permitted Priority Liens) perfected
lien on such Collateral, subject, for the following Collateral, to the occurrence of the following: (i) in the case of Collateral
in which a security interest may be perfected by filing a financing statement under the UCC, the filing of a UCC financing statement
naming such Grantor as debtor, the Secured Parties as secured parties, and listing all personal property as collateral, (ii) with
respect to any Deposit Account, Securities Account or Commodity Account, the execution of agreements among such Grantor, the applicable
financial institution and the Control Agent, effective to grant “control” (as defined in the UCC) over such Deposit
Account, Securities Account or Commodity Account to the Control Agent, (iii) with respect to any Intellectual Property not described
in the foregoing clause (i), the filing of this Security Agreement or a short-form security agreement with the applicable
Intellectual Property office of the applicable government, and (iv) in the case of all certificated Shares, the delivery thereof
to the Control Agent, properly endorsed for transfer to the Control Agent or in blank.


 


2.03    Names,
Etc. The full and correct legal name, type of organization, jurisdiction of organization, organizational ID number (if applicable)
and mailing address of such Grantor as of the date hereof are correctly set forth in Annex 1. Annex 1 correctly specifies
(i) the place of business of such Grantor or, if such Grantor has more than one place of business, the location of the chief executive
office of such Grantor, and (ii) each location where Collateral in excess of $250,000 is stored or located.


 


2.04    Changes
in Circumstances. Such Grantor has not (a) within the period of four months prior to the date hereof, changed its location
(as defined in Section 9-307 of the NYUCC), or (b) except as specified in Annex 1, heretofore changed its name.


 


2.05    Pledged
Shares. (a) The Initial Pledged Shares constitute (a) 100% of the issued and outstanding Shares of each Issuer (other than
a Controlled Foreign Corporation) beneficially owned by such Grantor on the date hereof (other than any Shares held in a Securities
Account referred to in Annex 7), whether or not registered in the name of such Grantor and (b) in the case of each Issuer
that is a Controlled Foreign Corporation, (i) 65% of the issued and outstanding shares of voting stock of such Issuer and (ii)
100% of all other issued and outstanding shares of capital stock of whatever class of such Issuer beneficially owned by such Grantor
on the date hereof, in each case whether or not registered in the name of such Grantor. Annex 2 correctly identifies, as
at the date hereof, the respective Issuers of the Initial Pledged Shares and (in the case of any corporate Issuer) the respective
class and par value of such Shares and the respective number of such Shares (and registered owner thereof) represented by each
such certificate.


 


(b)          The
Initial Pledged Shares are, and all other Pledged Shares that in the future will constitute Collateral will be, (i) duly authorized,
validly existing, fully paid and non-assessable (in the case of any Shares issued by a corporation) and (ii) duly issued and outstanding
(in the case of any equity interest in any other entity). None of such Pledged Shares are or will be subject to any contractual
restriction, or any restriction under the charter, bylaws, partnership agreement or other organizational instrument of the respective
Issuer thereof, upon the transfer of such Pledged Shares (except for any such restriction contained in or expressly permitted under
any Loan Document, including any Restrictive Agreement permitted under Section 9.11 of the Loan Agreement).


 




    	4



    	 



    

 


2.06    Promissory
Notes. Annex 3 sets forth a complete and correct list of all Promissory Notes (other than any held in a Securities Account
referred to in Annex 7) held by such Grantor on the date hereof.


 


2.07    Intellectual
Property. (a) Annexes 4, 5 and 6, respectively, set forth a complete and correct list of all of the following
owned by such Grantor on the date hereof (or, in the case of any supplement to said Annexes 4, 5 and 6, effecting
a pledge thereof, as of the date of such supplement): (i) applied for or registered Copyrights, (ii) applied for or registered
Patents, including the jurisdiction and patent number, (iii) applied for or registered Trademarks, including the jurisdiction,
trademark application or registration number and the application or registration date, and (iv) trade names.


 


(b)          Except
pursuant to licenses and other user agreements entered into by such Grantor in the ordinary course of business that are listed
in said Annexes 4, 5 and 6 (including as supplemented by any supplement effecting a pledge thereof), such
Grantor has done nothing to authorize or enable any other Person to use any Copyright, Patent or Trademark listed in said Annexes
4, 5 and 6 (as so supplemented), and all registrations listed in said Annexes 4, 5 and 6
(as so supplemented) are, except as noted therein, in full force and effect.


 


(c)          Such
Grantor owns and possesses the right to use all Copyrights, Patents and Trademarks listed on Annexes 4, 5 and 6,
respectively. To such Grantor’s knowledge, (i) except as set forth on Annex 4, 5 or 6 (as supplemented
by any supplement effecting a pledge thereof), there is no violation by others of any right of such Grantor with respect to any
Copyright, Patent or Trademark listed on Annex 4, 5 or 6 (as so supplemented), respectively, and (ii) such
Grantor is not infringing in any respect upon any Copyright, Patent or Trademark of any other Person. No proceedings alleging such
infringement have been instituted or are pending against such Grantor and no written claim against such Grantor has been received
by such Grantor, alleging any such violation, except as may be set forth on Annex 4, 5 or 6 (as so supplemented).


 


2.08    Deposit
Accounts, Securities Accounts and Commodity Accounts. Annex 7 sets forth a complete and correct list of all Deposit
Accounts, Securities Accounts and Commodity Accounts of such Grantor on the date hereof.


 


2.09    Commercial
Tort Claims. Annex 8 sets forth a complete and correct list of all commercial tort claims of such Grantor in existence
on the date hereof.


 


2.10    Update
of Annexes. Each of Annexes 1 through 8 may be updated by Borrower from time to time to insure the continued
accuracy of the representations set forth in this Section 2 to be made on any upcoming date on which representations and
warranties are made incorporating the information in such Annex, by Borrower providing notice (attaching an amended and restated
version of such Annex) in accordance with Section 12.02 of the Loan Agreement.


 




    	5



    	 



    

 


Section 3.          Collateral.


 


3.01    Granting
Clause. As collateral security for the payment in full when due (whether at stated maturity, by acceleration or otherwise)
of the Secured Obligations, each Grantor hereby pledges and grants to the Secured Parties as hereinafter provided a security interest
in all of such Grantor’s right, title and interest in, to and under all of its property, in each case whether tangible or
intangible, wherever located, and whether now owned by such Grantor or hereafter acquired and whether now existing or hereafter
coming into existence, including without limitation all of the following, but excluding all Excluded Assets (collectively, and
subject to the proviso at the end of this Section 3.01, “Collateral”):


 


(a)          all
Accounts:


 


(b)          all
As-Extracted Collateral;


 


(c)          all
Chattel Paper and other Records;


 


(d)          all
Checks;


 


(e)          all
commercial tort claims, as defined in Section 9-102(a)(13) of the NYUCC, arising out of the events described in Annex 8;


 


(f)          all
Deposit Accounts;


 


(g)          all
Documents;


 


(h)          all
Encumbrances;


 


(i)          all
Equipment;


 


(j)          all
Fixtures;


 


(k)          all
General Intangibles;


 


(l)          all
Goods not otherwise described in this Section 3;


 


(m)          all
Instruments, including all Promissory Notes;


 


(n)          all
Intellectual Property;


 


(o)          all
Inventory;


 


(p)          all
Letters of Credit and all Supporting Obligations;


 


(q)          all
Investment Property not otherwise described in this Section 3, including all Securities, all Securities Accounts and all
Security Entitlements with respect thereto and Financial Assets carried therein, and all Commodity Accounts and Commodity Contracts;


 




    	6



    	 



    

 


(r)          all
Pledged Shares; and


 


(s)          all
Proceeds of any of the foregoing, all Accessions to and substitutions and replacements for, any of the Collateral, and all offspring,
rents, profits and products of any of the Collateral, and, to the extent related to any Collateral, all books, correspondence,
credit files, records, invoices and other papers (including all tapes, cards, computer runs and other papers and documents in the
possession or under the control of such Grantor or any computer bureau or service company from time to time acting for such Grantor);


 


provided, however, that, nothing set forth in this Section
3.01 or any other provision of this Agreement or any other Loan Document shall at any time constitute the grant of a security
interest in, or a Lien on, any Excluded Asset, none of which shall constitute Collateral.


 


3.02    Controlled
Foreign Corporations; Certain Leases and Licenses. Notwithstanding anything herein to the contrary, in no event shall the Collateral
include, and each Grantor shall not be deemed to have granted a security interest in, any of such Grantor’s right, title
or interest in:


 


(a)          any
of the outstanding voting capital stock or other ownership interests of a Controlled Foreign Corporation in excess of 65% of the
voting power of all classes of capital stock or other ownership interests of such Controlled Foreign Corporation entitled to vote;
provided that (i) immediately upon the amendment of the Code to allow the pledge of a greater percentage of the voting power of
capital stock or other ownership interests in a Controlled Foreign Corporation without adverse tax consequences, the Collateral
shall include, and each Grantor shall be deemed to have granted a security interest in, such greater percentage of capital stock
or other ownership interests of each Controlled Foreign Corporation in which it has any interest and (ii) if no adverse tax consequences
to the applicable Grantor shall arise or exist in connection with the pledge of any Controlled Foreign Corporation, the Collateral
shall include, and the applicable Grantor shall be deemed to have granted a security interest in, all of the capital stock or other
ownership interests of such Controlled Foreign Corporation held by such Grantor;


 


(b)          any
lease, license, contract or agreement to which any Grantor is a party, in each case, if and only if, and solely to the extent that,
(A) the grant of a security interest therein shall constitute or result in a breach, termination or default or invalidity thereunder
or thereof (other than to the extent that any such term would be rendered ineffective pursuant to Sections 9-406, 9-407, 9-408
or 9-409 of the UCC of any relevant jurisdiction or any other applicable law or principles of equity) and (B) such lease, license,
contract or agreement (1) is an “off the shelf” license of intellectual property that is not material to the operation
of the business of the applicable Grantor or which can be replaced without a material expenditure, or (2) is executed by the applicable
Grantor after the date hereof (provided that the applicable Grantor, prior to entering into or obtaining such lease, license, contract
or agreement, used commercially reasonable efforts to permit the collateral assignment thereof but was unsuccessful in obtaining
such permission); provided that immediately upon the time at which the consequences described in the foregoing clause (A) shall
no longer exist, the Collateral shall include, and the applicable Grantor shall be deemed to have granted a security interest in,
all of such Grantor’s right, title and interest in such lease, license, contract or agreement; or


 




    	7



    	 



    

 


(c)          any
application for registration of a trademark filed on an intent-to-use basis solely to the extent that the grant of a security interest
in any such trademark application would materially adversely affect the validity or enforceability of the resulting trademark registration
or result in cancellation of such trademark application.


 


Section 4.          Further
Assurances; Remedies. In furtherance of the grant of the security interest pursuant to Section 3, the Grantors hereby
jointly and severally agree with the Secured Parties as follows:


 


4.01    Delivery
and Other Perfection. Each Grantor shall promptly from time to time give, execute, deliver, file, record, authorize or obtain
all such financing statements, continuation statements, notices, instruments, documents, agreements or consents or other papers
as may be necessary or desirable in the judgment of the Majority Lenders to create, preserve, perfect, maintain the perfection
of or validate the security interest granted pursuant hereto or to enable the Secured Parties to exercise and enforce their rights
hereunder with respect to such security interest, and without limiting the foregoing, shall:


 


(a)          if
any of the Pledged Shares, Investment Property or Financial Assets constituting part of the Collateral are received by the Grantor,
forthwith (x) deliver to the Control Agent the certificates or instruments representing or evidencing the same, duly endorsed in
blank or accompanied by such instruments of assignment and transfer in such form and substance as the Control Agent may request,
all of which thereafter shall be held by the Control Agent, pursuant to the terms of this Agreement, as part of the Collateral
and (y) take such other action as the Control Agent may deem necessary or appropriate to duly record or otherwise perfect the security
interest created hereunder in such Collateral;


 


(b)          promptly
from time to time deliver to the Control Agent any and all Instruments constituting part of the Collateral, endorsed and/or accompanied
by such instruments of assignment and transfer in such form and substance as the Control Agent may request; provided that
(other than in the case of the Promissory Notes described in Annex 3) until the occurrence of an Event of Default that has
not been waived in writing by the Majority Lenders in accordance with the Loan Agreement, such Grantor may retain for collection
in the ordinary course any Instruments received by such Grantor in the ordinary course of business and the Control Agent shall,
promptly upon request of such Grantor, make appropriate arrangements for making any Instrument delivered by such Grantor available
to such Grantor for purposes of presentation, collection or renewal (any such arrangement to be effected, to the extent requested
by the Control Agent, against trust receipt or like document);


 


(c)          promptly
from time to time enter into such control agreements, each in form and substance acceptable to the Majority Lenders, as may be
required to perfect the security interest created hereby in any and all Deposit Accounts, Investment Property, Electronic Chattel
Paper and Letter-Of-Credit Rights, and will promptly furnish to the Control Agent true copies thereof;


 




    	8



    	 



    

 


(d)          promptly
from time to time upon the request of the Control Agent, (i) execute and deliver such short-form security agreements as the Majority
Lenders may deem necessary or desirable to protect the interests of the Secured Parties in respect of that portion of the Collateral
consisting of Intellectual Property, and (ii) take such other action as the Majority Lenders may deem necessary or appropriate
duly to record or otherwise perfect the security interest created hereunder in that portion of the Collateral consisting of Intellectual
Property registered or located outside of the United States;


 


(e)          promptly
upon request of the Control Agent, cause the Secured Parties to be listed as the lienholder on any certificate of title or ownership
covering any Motor Vehicle (other than Motor Vehicles constituting Inventory) and within 120 days of such request deliver evidence
of the same to the Control Agent;


 


(f)          keep
full and accurate books and records relating to the Collateral, and stamp or otherwise mark such books and records in such manner
as the Majority Lenders may require in order to reflect the security interests granted by this Agreement;


 


(g)          permit
representatives of the Secured Parties, upon reasonable notice, at any time during normal business hours to inspect and make abstracts
from its books and records pertaining to the Collateral, and permit representatives of the Secured Parties to be present at such
Grantor’s place of business to receive copies of communications and remittances relating to the Collateral, and forward copies
of any notices or communications received by such Grantor with respect to the Collateral, all in such manner as the Majority Lenders
may require; and


 


(h)          (i)
promptly from time to time upon the request of the Majority Lenders, use commercially reasonable efforts to execute and deliver
such real property security documents, landlord consents and collateral access agreements with respect to real Property owned or
leased (as tenant) by such Grantor in the United States, (ii) obtain a bailee waiver or other agreement from the lessor of each
leased property, the mortgagee of owned property or bailee or consignee with respect to any warehouse, processor or converted facility
or other location where Collateral in excess of $250,000 is stored or located and (iii) cause to be recorded in the appropriate
real property records such documents delivered pursuant to this Section 4.01(h) as the Control Agent may deem necessary
or appropriate.


 


4.02    Other
Financing Statements or Control. Except as otherwise permitted under the Loan Documents, no Grantor shall (a) file or suffer
to be on file, or authorize or permit to be filed or to be on file, in any jurisdiction, any financing statement or like instrument
with respect to any of the Collateral in which the Secured Parties are not named as the sole secured parties (except to the extent
that such financing statement or instrument relates to a Permitted Lien), or (b) cause or permit any Person other than the Control
Agent or the Secured Parties or any holder of a Permitted Priority Lien to have “control” (as defined in Section 9-104,
9-105, 9-106 or 9-107 of the NYUCC) of any Deposit Account, Securities Account, Commodity Account, Electronic Chattel Paper, Investment
Property or Letter-Of-Credit Right constituting part of the Collateral.


 


4.03    Preservation
of Rights. The Secured Parties shall not be required to take steps necessary to preserve any rights against prior parties to
any of the Collateral.


 




    	9



    	 



    

 


4.04    Special
Provisions Relating to Certain Collateral. (a) Pledged Shares.


 


(i)          The
Grantors will cause the Pledged Shares to constitute at all times (1) 100% of the total number of Shares of each Issuer (other
than a Controlled Foreign Corporation) then outstanding owned by the Grantors and (2) in the case of any Issuer that is a Controlled
Foreign Corporation, 65% of the total number of shares of voting stock of such Issuer and 100% of the total number of shares of
all other classes of capital stock of such Issuer then issued and outstanding owned by the Grantors.


 


(ii)         Until
the occurrence of an Event of Default that has not been waived in writing by the Majority Lenders in accordance with the Loan Agreement,
the Grantors shall have the right to exercise all voting, consensual and other powers of ownership pertaining to the Pledged Shares
for all purposes not inconsistent with the terms of this Agreement, the other Loan Documents or any other instrument or agreement
referred to herein or therein, provided that the Grantors jointly and severally agree that they will not vote the Pledged Shares
in any manner that is inconsistent with the terms of this Agreement, the other Loan Documents or any such other instrument or agreement;
and the Control Agent and Secured Parties shall execute and deliver to the Grantors or cause to be executed and delivered to the
Grantors all such proxies, powers of attorney, dividend and other orders, and all such instruments, without recourse, as the Grantors
may reasonably request for the purpose of enabling the Grantors to exercise the rights and powers that it is entitled to exercise
pursuant to this Section 4.04(a)(ii).


 


(iii)        Until
the occurrence of an Event of Default that has not been waived in writing by the Majority Lenders in accordance with the Loan Agreement,
the Grantors shall be entitled to receive and retain any dividends, distributions or proceeds on the Pledged Shares paid in cash
out of earned surplus.


 


(iv)         After
the occurrence of an Event of Default that has not been waived in writing by the Majority Lenders in accordance with the Loan Agreement,
whether or not the Secured Parties or any of them exercises any available right to declare any Secured Obligations due and payable
or seeks or pursues any other relief or remedy available to them under applicable law or under this Agreement, the other Loan Documents
or any other agreement relating to such Secured Obligation, all dividends and other distributions on the Pledged Shares shall be
paid directly to the Secured Parties Representative for distribution to the Secured Parties and retained by them as part of the
Collateral, subject to the terms of this Agreement, and, if the Secured Parties Representative shall so request in writing, the
Grantors jointly and severally agree to execute and deliver to the Secured Parties Representative appropriate additional dividend,
distribution and other orders and documents to that end, provided that if such Event of Default is waived in writing by the Majority
Lenders in accordance with the Loan Agreement, any such dividend or distribution theretofore paid to the Secured Parties Representative
shall, upon request of the Grantors (except to the extent theretofore applied to the Secured Obligations), be returned by the Secured
Parties Representative to the Grantors.


 




    	10



    	 



    

 


(b)          Intellectual
Property. (i) For the purpose of enabling the Secured Parties to exercise rights and remedies under Section 4.05 at
such time as the Secured Parties shall be lawfully entitled to exercise such rights and remedies, and for no other purpose, each
Grantor hereby grants to the Secured Parties Representative, to the extent assignable, an irrevocable, non-exclusive license (exercisable
without payment of royalty or other compensation to such Grantor) to use, and the right to assign, license or sublicense, any of
the Intellectual Property now owned or hereafter acquired by such Grantor, wherever the same may be located, including in such
license reasonable access to all media in which any of the licensed items may be recorded or stored and to all computer programs
used for the compilation or printout thereof.


 


(ii)         Notwithstanding
anything contained herein to the contrary, but subject to any provision of the Loan Documents that limits the rights of any Grantor
to dispose of its property, until the occurrence of an Event of Default that has not been waived in writing by the Majority Lenders
in accordance with the Loan Agreement, the Grantors will be permitted to exploit, use, enjoy, protect, defend, enforce, license,
sublicense, assign, sell, dispose of or take other actions with respect to the Intellectual Property in the ordinary course of
the business of the Grantors. In furtherance of the foregoing, until the occurrence of an Event of Default that has not been waived
in writing by the Majority Lenders in accordance with the Loan Agreement, the Secured Parties or the Secured Parties Representative
shall from time to time, upon the request of the respective Grantor, execute and deliver any instruments, certificates or other
documents, in the form so requested, that the Grantors shall have certified are appropriate in its judgment to allow it to take
any action permitted above (including relinquishment of the license provided pursuant to Section 4.04(b)(i) as to any specific
Intellectual Property). Further, upon the payment in full of all of the Secured Obligations (other than contingent indemnification
obligations for which no claim has been made) or earlier expiration of this Agreement or release of the Collateral, the Secured
Parties Representative shall grant back to the Grantors the license granted pursuant to Section 4.04(b)(i). The exercise
of rights and remedies under Section 4.05 by the Secured Parties shall not terminate the rights of the holders of any licenses,
covenants not to sue or sublicenses theretofore granted by the Grantors in accordance with the first sentence of this Section
4.04(b)(ii).


 


(c)          Chattel
Paper. The Grantors will (i) deliver to the Control Agent each original of each item of Chattel Paper at any time constituting
part of the Collateral, and (ii) cause each such original and each copy thereof to bear a conspicuous legend, in form and substance
satisfactory to the Control Agent, indicating that such Chattel Paper is subject to the security interest granted hereby and that
purchase of such Chattel Paper by a Person other than the Control Agent without the consent of the Control Agent would violate
the rights of the Secured Parties.


 


4.05    Remedies.
(a) Rights and Remedies Generally upon Event of Default. Upon the occurrence of an Event of Default that has not been waived
in writing by the Majority Lenders in accordance with the Loan Agreement, the Secured Parties shall have all of the rights and
remedies with respect to the Collateral of a secured party under the NYUCC (whether or not the Uniform Commercial Code is in effect
in the jurisdiction where the rights and remedies are asserted) and such additional rights and remedies to which a secured party
is entitled under the laws in effect in any jurisdiction where any rights and remedies hereunder may be asserted, including the
right, to the fullest extent permitted by law, to exercise all voting, consensual and other powers of ownership pertaining to the
Collateral as if the Secured Parties were the sole and absolute owner thereof (and each Grantor agrees to take all such action
as may be appropriate to give effect to such right). Upon the occurrence of an Event of Default that has not been waived in writing
by the Majority Lenders in accordance with the terms of the Loan Agreement, the Majority Lenders shall appoint one of the Secured
Parties to act as a representative of all the Secured Parties (such Person, the “Secured Parties Representative”)
to exercise, on behalf of all the Secured Parties, such rights and remedies of the Secured Parties described above; and without
limiting the foregoing:


 




    	11



    	 



    

 


(i)          the
Secured Parties Representative may, in their name or in the name of any Grantor or otherwise, demand, sue for, collect or receive
any money or other property at any time payable or receivable on account of or in exchange for any of the Collateral, but shall
be under no obligation to do so;


 


(ii)         the
Secured Parties Representative may make any reasonable compromise or settlement deemed desirable with respect to any of the Collateral
and may extend the time of payment, arrange for payment in installments, or otherwise modify the terms of, any of the Collateral;


 


(iii)        the
Secured Parties Representative may require the Grantors to notify (and each Grantor hereby authorizes the Secured Parties Representative
to so notify) each account debtor in respect of any Account, Chattel Paper or General Intangible, and each obligor on any Instrument,
constituting part of the Collateral that such Collateral has been assigned to the Secured Parties hereunder, and to instruct that
any payments due or to become due in respect of such Collateral shall be made directly to the Secured Parties Representative or
as it may direct (and if any such payments, or any other Proceeds of Collateral, are received by any Grantor they shall be held
in trust by such Grantor for the benefit of the Secured Parties and as promptly as possible remitted or delivered to the Secured
Parties Representative for application as provided herein);


 


(iv)         the
Secured Parties Representative may require the Grantors to assemble the Collateral at such place or places, convenient to the Secured
Parties and the Grantors, as the Secured Parties Representative may direct;


 


(v)          the
Secured Parties Representative may require the Grantors to cause the Pledged Shares to be transferred of record into the name of
the Secured Parties Representative or its nominee (and the Secured Parties Representative agrees that if any of such Pledged Shares
are transferred into its name or the name of its nominee, the Secured Parties Representative will thereafter promptly give to the
respective Grantor copies of any notices and communications received by it with respect to such Pledged Shares); and


 


(vi)         the
Secured Parties Representative may sell, lease, assign or otherwise dispose of all or any part of the Collateral, at such place
or places as the Secured Parties Representative deems best, and for cash or for credit or for future delivery (without thereby
assuming any credit risk), at public or private sale, without demand of performance or notice of intention to effect any such disposition
or of the time or place thereof (except such notice as is required by applicable statute and cannot be waived), and the Secured
Parties, Secured Parties Representative or anyone else may be the purchaser, lessee, assignee or recipient of any or all of the
Collateral so disposed of at any public sale (or, to the extent permitted by law, at any private sale) and thereafter hold the
same absolutely, free from any claim or right of whatsoever kind, including any right or equity of redemption (statutory or otherwise),
of the Grantors, any such demand, notice and right or equity being hereby expressly waived and released. In the event of any sale,
assignment, or other disposition of any of the Collateral consisting of Trademarks, the goodwill connected with and symbolized
by the Trademarks subject to such disposition shall be included. The Secured Parties Representative may, without notice or publication,
adjourn any public or private sale or cause the same to be adjourned from time to time by announcement at the time and place fixed
for the sale, and such sale may be made at any time or place to which the sale may be so adjourned.


 




    	12



    	 



    

 


(vii)        The
Proceeds of each collection, sale or other disposition under this Section 4.05, including by virtue of the exercise of any
license granted to the Secured Parties Representative in Section 4.04(b), shall be applied in accordance with Section
4.09.


 


(b)          Certain
Securities Act Limitations. The Grantors recognize that, by reason of certain prohibitions contained in the Securities Act
of 1933, as amended, and applicable state securities laws, the Secured Parties Representative may be compelled, with respect to
any sale of all or any part of the Collateral, to limit purchasers to those who will agree, among other things, to acquire the
Collateral for their own account, for investment and not with a view to the distribution or resale thereof. The Grantors acknowledge
that any such private sales may be at prices and on terms less favorable to the Secured Parties Representative than those obtainable
through a public sale without such restrictions, and, notwithstanding such circumstances, agree that any such private sale shall
be deemed to have been made in a commercially reasonable manner and that the Secured Parties Representative shall have no obligation
to engage in public sales and no obligation to delay the sale of any Collateral for the period of time necessary to permit the
issuer thereof to register it for public sale.


 


(c)          Notice.
The Grantors agree that to the extent the Secured Parties Representative is required by applicable law to give reasonable prior
notice of any sale or other disposition of any Collateral, ten business days’ notice shall be deemed to constitute reasonable
prior notice.


 


(d)          No
Assumption of Obligations. Notwithstanding any provision in this Agreement or any other Loan Document to the contrary, the
Secured Parties are not assuming any liability or obligation of any Grantor or any of its Affiliates of whatever nature, whether
presently in existence or arising or asserted hereafter. All such liabilities and obligations shall be retained by and remain obligations
and liabilities of the applicable Grantor and/or its Affiliates, as the case may be. Without limiting the foregoing, the Secured
Parties are not assuming and shall not be responsible for any liabilities or Claims of any Grantor or its Affiliates, whether present
or future, absolute or contingent and whether or not relating to a Grantor, the Obligor Intellectual Property, and/or the Material
Agreements, and each Grantor shall indemnify and save harmless the Secured Parties from and against all such liabilities, Claims
and Liens.


 


4.06    Deficiency.
If the proceeds of sale, collection or other realization of or upon the Collateral pursuant to Section 4.05 are insufficient
to cover the costs and expenses of such realization and the indefeasible payment in full in cash of the Secured Obligations (other
than contingent indemnification obligations for which no claim has been made), the Grantors shall remain liable for any deficiency.


 




    	13



    	 



    

 


4.07    Locations;
Names, Etc. No Grantor shall (i) change its location (as defined in Section 9-307 of the NYUCC), (ii) change its name from
the name shown as its current legal name on Annex 1, or (iii) agree to or authorize any modification of the terms of any
item of Collateral that would result in a change thereof from one Uniform Commercial Code category to another such category (such
as from a General Intangible to Investment Property), if the effect thereof would be to result in a loss of perfection of, or diminution
of priority for, the security interests created hereunder in such item of Collateral, or the loss of control (within the meaning
of Section 9-104, 9-105, 9-106 or 9-107 of the NYUCC) over such item of Collateral, unless in each case 30 days’ prior written
notice has been provided to the Control Agent and such change is not otherwise restricted by the terms of any Loan Document.


 


4.08    Private
Sale. The Secured Parties shall incur no liability as a result of the sale of the Collateral, or any part thereof, at any private
sale pursuant to Section 4.05 conducted in a commercially reasonable manner. Each Grantor hereby waives any claims against
the Secured Parties Representative, the Secured Parties or any of them arising by reason of the fact that the price at which the
Collateral may have been sold at such a private sale was less than the price that might have been obtained at a public sale or
was less than the aggregate amount of the Secured Obligations, even if the Secured Parties Representative, the Secured Parties
or any of them accepts the first offer received and does not offer the Collateral to more than one offeree.


 


4.09    Application
of Proceeds. Except as otherwise herein expressly provided and except as provided below in this Section 4.09, the Proceeds
of any collection, sale or other realization of all or any part of the Collateral pursuant hereto, and any other cash at the time
held by the Control Agent or the Secured Parties under this Section 4, shall be applied by the Control Agent or the Secured
Parties (as the case may be):


 


First, to the payment of the costs and expenses
of such collection, sale or other realization, including reasonable out of pocket costs and expenses of the Secured Parties and
the fees and expenses of their agents and counsel, and all expenses incurred and advances made by the Secured Parties in connection
therewith;


 


Next, to the indefeasible payment in full
of the Secured Obligations (other than contingent indemnification obligations for which no claim has been made) in such order as
the Secured Parties in their sole discretion shall determine; and


 


Finally, to the payment to respective Grantor,
or its successors or assigns, or as a court of competent jurisdiction may direct, of any surplus then remaining.


 


4.10    Attorney
in Fact. Without limiting any rights or powers granted by this Agreement to the Secured Parties, upon the occurrence of an
Event of Default that has not been waived in writing by the Majority Lenders in accordance with the Loan Agreement, the Secured
Parties Representative (and any of its officers, employees or agents) hereby is appointed the attorney in fact of each Grantor
for the purpose of carrying out the provisions of this Section 4 and taking any action and executing any instruments that
the Secured Parties Representative may deem necessary or advisable to accomplish the purposes hereof, which appointment as attorney
in fact is irrevocable and coupled with an interest. Without limiting the generality of the foregoing, so long as the Secured Parties
Representative shall be entitled under this Section 4 to make collections in respect of the Collateral, the Secured Parties
Representative shall have the right and power to receive, endorse and collect all checks made payable to the order of any Grantor
representing any dividend, payment or other distribution in respect of the Collateral or any part thereof and to give full discharge
for the same.


 




    	14



    	 



    

 


4.11    Perfection
and Recordation. Each Grantor authorizes the Secured Parties to file Uniform Commercial Code financing statements describing
the Collateral as “all assets” or “all personal property and fixtures” of such Grantor (provided that no
such description shall be deemed to modify the description of Collateral set forth in Section 3).


 


4.12    Termination.
When all Secured Obligations (other than contingent indemnification obligations for which no claim has been made) shall have been
indefeasibly paid in full in cash, this Agreement automatically shall terminate, and the Secured Parties shall, upon request of
Grantors, cause to be assigned, transferred and delivered, against receipt but without any recourse, warranty or representation
whatsoever, any remaining Collateral and money received in respect thereof, to or on the order of the respective Grantor and to
be released and canceled all licenses and rights referred to in Section 4.04(b), in each case, at Grantors’ sole expense.
The Secured Parties shall also, at the expense of such Grantor, execute and deliver to such Grantor upon such termination such
Uniform Commercial Code termination statements, certificates for terminating the liens on the Motor Vehicles and such other documentation
as shall be reasonably requested by the respective Grantor to effect the termination and release of the liens on the Collateral
as required by this Section 4.12, in each case, at Grantors’ sole expense.


 


4.13    Further
Assurances. Each Grantor agrees that, from time to time upon the written request of the Majority Lenders, such Grantor will
execute and deliver such further documents and do such other acts and things as the Majority Lenders may request in order fully
to effect the purposes of this Agreement. The Secured Parties shall release any lien covering any asset that has been disposed
of in accordance with the provisions of the Loan Documents.


 


Section 5.          Miscellaneous.


 


5.01    Notices.
All notices, requests, consents and demands hereunder shall be delivered in accordance with Section 12.02 of the Loan Agreement.


 


5.02    No
Waiver. No failure on the part of any Secured Party to exercise, and no course of dealing with respect to, and no delay in
exercising, any right, power or remedy hereunder shall operate as a waiver thereof; nor shall any single or partial exercise by
any Secured Party of any right, power or remedy hereunder preclude any other or further exercise thereof or the exercise of any
other right, power or remedy. The remedies herein are cumulative and are not exclusive of any remedies provided by law.


 


5.03    Amendments,
Etc. The terms of this Agreement may be waived, altered or amended only by an instrument in writing duly executed by each Grantor
and the Majority Lenders (unless the consent of each Secured Party is required in accordance with Section 12.04 of the Loan
Agreement).


 


5.04    Expenses.


 




    	15



    	 



    

 


(a)          The
Grantors shall pay or reimburse the Control Agent or the Secured Parties for costs and expenses in accordance with Section 12.03
of the Loan Agreement.


 


(b)          The
Grantors shall hereby indemnify the Secured Parties, their Affiliates, and their respective directors, officers, employees, attorneys,
agents, advisors and controlling parties in accordance with Section 12.03(b) of the Loan Agreement.


 


5.05    Successors
and Assigns. This Agreement shall be binding upon and inure to the benefit of the respective successors and assigns of each
Grantor, the Control Agent, the Secured Parties Representative and the Secured Parties (provided that no Grantor shall assign or
transfer its rights or obligations hereunder unless consented to in writing by the Majority Lenders in accordance with the Loan
Agreement).


 


5.06    Counterparts.
This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument
and any of the parties hereto may execute this Agreement by signing any such counterpart.


 


5.07    Governing
Law; Submission to Jurisdiction; Etc. (a) Governing Law. This Agreement and the rights and obligations of the parties
hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles
of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401
of the New York General Obligations Law shall apply.


 


(b)          Submission
to Jurisdiction. Each Grantor agrees that any suit, action or proceeding with respect to this Agreement or any other Loan Document
to which it is a party or any judgment entered by any court in respect thereof may be brought initially in the federal or state
courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction
of each such court for the purpose of any such suit, action, proceeding or judgment. This Section 5.07(b) is for the benefit
of the Secured Parties only and, as a result, no Secured Party shall be prevented from taking proceedings in any other courts with
jurisdiction. To the extent allowed by applicable Laws, the Secured Parties may take concurrent proceedings in any number of jurisdictions.


 


(c)          Waiver
of Venue. Each Grantor irrevocably waives to the fullest extent permitted by law any objection that it may now or hereafter
have to the laying of the venue of any suit, action or proceeding arising out of or relating to this Agreement and hereby further
irrevocably waives to the fullest extent permitted by law any claim that any such suit, action or proceeding brought in any such
court has been brought in an inconvenient forum. A final judgment (in respect of which time for all appeals has elapsed) in any
such suit, action or proceeding shall be conclusive and may be enforced in any court to the jurisdiction of which such Grantor
is or may be subject, by suit upon judgment.


 


(d)          Service
of Process. Each party to this Agreement irrevocably consents to service of process in the manner provided for notices in Section
5.01. Nothing in this Agreement will affect the right of any party to this Agreement to serve process in any other manner permitted
by law.


 




    	16



    	 



    

 


5.08    WAIVER
OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO
A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE,
AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO
ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 5.08.


 


5.09    Captions.
The captions and section headings appearing herein are included solely for convenience of reference and are not intended to affect
the interpretation of any provision of this Agreement.


 


5.10    Agents
and Attorneys in Fact. The Secured Parties may employ agents and attorneys in fact in connection herewith and shall not be
responsible for the negligence or misconduct of any such agents or attorneys in fact selected by it in good faith.


 


5.11    Severability.
If any provision hereof is invalid and unenforceable in any jurisdiction, then, to the fullest extent permitted by law, (a) the
other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in favor of
the Secured Parties in order to carry out the intentions of the parties hereto as nearly as may be possible and (b) the invalidity
or unenforceability of any provision hereof in any jurisdiction shall not affect the validity or enforceability of such provision
in any other jurisdiction.


 


5.12    Additional
Grantors. Additional Persons may from time to time after the date of this Agreement become Grantors under this Agreement by
executing and delivering to the Control Agent a supplemental agreement (together with all schedules thereto, a “Joinder”)
to this Agreement, in substantially the form attached hereto as Exhibit A. Accordingly, upon the execution and delivery
of any such Joinder by any such Person, such Person shall automatically and immediately, and without any further action on the
part of any Person, become a “Grantor” under and for all purposes of this Agreement, and each of the Annexes hereto
shall be supplemented in the manner specified in such Joinder. In addition, upon the execution and delivery of any such Joinder,
the new Grantor makes the representations and warranties set forth in Section 2.


 




    	17



    	 



    

 


5.13    Limited
Agency for Perfection. (a) The Secured Parties each hereby appoint Capital Royalty Partners II L.P. as their collateral agent
(in such capacity, together with any successor in such capacity appointed by Capital Royalty Partners II L.P. and consented to
in writing by the Majority Lenders in accordance with the Loan Agreement (such consent not to be unreasonably withheld or delayed),
the “Control Agent”) for the limited purpose of acting as the agent on behalf of the Secured Parties
with respect to the Pledged Property for purposes of the perfecting of the Liens of the Secured Parties on the Pledged Property.
The Control Agent accepts such appointment and agrees to hold or to have control of, as applicable, the Pledged Property for the
benefit of itself and the other Secured Parties and any permitted assignee of any thereof solely for the purpose of perfecting
the security interest granted to such parties in such Pledged Property, subject to the terms and conditions of this Section
5.13. All Secured Parties hereby agree that the Control Agent shall have the sole and exclusive right and authority to give
instructions to, and otherwise direct, the Grantors in respect of the Pledged Property and no other Secured Party will hinder,
delay or interfere with the exercise of such rights by the Control Agent in any respect. The Grantors hereby agree to pay, reimburse,
indemnify and hold harmless the Control Agent for any claims or losses related to its acting in such role except to the extent
due to the gross negligence or willful misconduct of the Control Agent. Except as specifically prescribed herein, the Control Agent
shall have no obligation whatsoever to the other Secured Parties including any obligation to assure that the Pledged Property is
genuine or owned by a Grantor or to preserve rights or benefits of any Person except as expressly set forth in this Section
5.13. In acting on behalf of the other Secured Parties, the duties or responsibilities of the Control Agent under this Section
5.13 shall be limited solely to physically holding the Pledged Property delivered to the Control Agent by the Grantors, and
entering into control agreements for the benefit of the Secured Parties, in each case, for purposes of perfecting the Lien held
by the Secured Parties.


 


(b)          The
Control Agent shall not have by reason of any document including this Agreement a fiduciary relationship in respect of any other
Secured Party.


 


(c)          The
Control Agent may perform any of its duties under this Agreement by or through its officers, directors, agents, employees, affiliates
or other designees.


 


[SIGNATURE PAGES FOLLOW]


 




    	18



    	 



    

 


IN WITNESS WHEREOF, the parties hereto have
caused this Security Agreement to be duly executed and delivered as of the day and year first above written.


 


	 	NAVIDEA PHARMACEUTICALS, INC., as 

Grantor
	 	 
	 	By	/s/ Brent L. Larson
	 	 	Name: Brent L. Larson 
	 	 	Title: Executive Vice President & CFO
	 	 	 
	 	MACROPHAGE THERAPEUTICS, INC., as 

Grantor
	 	 	 
	 	By	/s/ Brent L. Larson
	 	 	Name: Brent L. Larson
	 	 	Title: Secretary


 


[Signature Page to Security Agreement]


 




    	 



    	 



    

 


	CAPITAL ROYALTY PARTNERS II L.P., 

as Secured Party and as Control Agent	 
	 	By CAPITAL ROYALTY PARTNERS II GP L.P., 

its General Partner	 
	 	 	By CAPITAL ROYALTY PARTNERS II GP LLC, 

its General Partner	 
	 	 	 	 
	 	 	By 	/s/ Charles Tate	 
	 	 	 	Name: Charles Tate	 
	 	 	 	Title: Sole Member	 
	 	 	 	 
	CAPITAL ROYALTY PARTNERS II – 

PARALLEL FUND “A” L.P., as Secured Party	 
	 	By CAPITAL ROYALTY PARTNERS II – 

PARALLEL FUND “A” GP L.P., its General 

Partner	 
	 	 	By CAPITAL ROYALTY PARTNERS II – 

PARALLEL FUND “A” GP LLC, 

its General Partner	 
	 	 	 	 
	 	 	By 	/s/ Charles Tate	 
	 	 	 	Name: Charles Tate	 
	 	 	 	Title: Sole Member	 
	 	 	 	 
	PARALLEL INVESTMENT OPPORTUNITIES 

PARTNERS II L.P., as Secured Party	 
	 	By PARALLEL INVESTMENT 

OPPORTUNITIES PARTNERS II GP L.P., 

its General Partner	 
	 	 	By PARALLEL INVESTMENT 

OPPORTUNITIES PARTNERS II GP LLC, 

its General Partner	 
	 	 	 	 
	 	 	By 	/s/ Charles Tate	 
	 	 	 	Name: Charles Tate	 
	 	 	 	Title: Sole Member	 


 


[Signature Page to Security Agreement]


 




    	 



    	 



    

 


EXHIBIT A

to Security Agreement


 


Form of Joinder
Agreement


 


JOINDER AGREEMENT dated as of [__________]
by [NAME OF ADDITIONAL GRANTOR], a [__________] corporation (the “Additional Grantor”), in favor of CAPITAL
ROYALTY PARTNERS II L.P., CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” L.P. and PARALLEL INVESTMENT OPPORTUNITIES
PARTNERS II L.P. (together, the “Secured Parties” and each, a “Secured Party”)
under the Loan Agreement referred to below.


 


A.           Reference
is made to (i) the Term Loan Agreement (as amended, supplemented, restated, extended, renewed or replaced from time to time, the
“Loan Agreement”), dated as of May __, 2015, among Navidea Pharmaceuticals, Inc., a Delaware corporation
(“Borrower”), Macrophage Therapeutics, Inc., a Delaware corporation (“Macrophage”),
the other Grantors from time to time party thereto and the Secured Parties, and (ii) the Security Agreement (as amended, supplemented,
restated, extended, renewed or replaced from time to time, the “Security Agreement”; capitalized terms
used herein by not defined shall have the meaning ascribed to such terms therein), dated as of May __, 2015, among the Grantors
party thereto, the Secured Parties and the Control Party.


 


B.           Section
5.12 of the Security Agreement provides that additional Persons may from time to time after the date of the Security Agreement
become Grantors under the Security Agreement by executing and delivering to the Secured Parties a supplemental agreement to the
Security Agreement in the form of this Joinder.


 


C.           To
induce the Secured Parties to maintain the term loans pursuant to the Loan Agreement, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Additional Grantor has agreed to execute and deliver (i) a Guarantee
Assumption Agreement under the Loan Agreement, and (ii) this Joinder to the Secured Parties.


 


The Additional Grantor hereby agrees to
become a “Grantor” for all purposes of the Security Agreement (and hereby supplements each of the Annexes to the Security
Agreement in the manner specified in Appendix A hereto). Without limitation, as collateral security for the payment in full
when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations (other than contingent indemnification
obligations for which no claim has been made), the Additional Grantor hereby pledges and grants to the Secured Parties as provided
in Section 3 of the Security Agreement a security interest in all of the Additional Grantor’s right, title and interest
in, to and under the Collateral of the Additional Grantor, in each case whether tangible or intangible, wherever located, and whether
now owned by the Additional Grantor or hereafter acquired and whether now existing or hereafter coming into existence. In addition,
the Additional Grantor hereby makes the representations and warranties set forth in Section 2 of the Security Agreement,
with respect to itself and its obligations under this Agreement, as if each reference in such Sections to the Loan Documents included
reference to this Agreement.


 


[SIGNATURE PAGES FOLLOW]


 




    	Exhibit A-1



    	 



    

 


IN WITNESS WHEREOF, the Additional Grantor
has caused this Joinder Agreement to be duly executed and delivered as of the day and year first above written.


 


	 	[INSERT NAME OF ADDITIONAL GRANTOR], 

as Grantor
	 	 
	 	By	 
	 	 	Name:
	 	 	Title:


 


 


	CAPITAL ROYALTY PARTNERS II L.P., 

as Secured Party and as Control Agent	 
	 	By CAPITAL ROYALTY PARTNERS II GP 

L.P., its General Partner	 
	 	 	By CAPITAL ROYALTY PARTNERS II 

GP LLC, its General Partner	 
	 	 	 	 
	 	 	By 	 	 
	 	 	 	Name: Charles Tate	 
	 	 	 	Title: Sole Member	 
	 	 	 	 
	CAPITAL ROYALTY PARTNERS II – 

PARALLEL FUND “A” L.P., as Secured Party	 
	 	By CAPITAL ROYALTY PARTNERS II – 

PARALLEL FUND “A” GP L.P., its General 

Partner	 
	 	 	By CAPITAL ROYALTY PARTNERS II – 

PARALLEL FUND “A” GP LLC, 

its General Partner	 
	 	 	 	 
	 	 	By 	 	 
	 	 	 	Name: Charles Tate	 
	 	 	 	Title: Sole Member	 
	 	 	 	 
	PARALLEL INVESTMENT OPPORTUNITIES 

PARTNERS II L.P., as Secured Party	 
	 	By PARALLEL INVESTMENT 

OPPORTUNITIES PARTNERS II GP L.P., 

its General Partner	 
	 	 	By PARALLEL INVESTMENT 

OPPORTUNITIES PARTNERS II GP LLC, 

its General Partner	 
	 	 	 	 
	 	 	By 	 	 
	 	 	 	Name: Charles Tate	 
	 	 	 	Title: Sole Member	 









 




    	Exhibit A-2



    	 



    

 


Appendix A


SUPPLEMENT[S] TO ANNEX[ES] TO SECURITY AGREEMENT


Supplement to Annex 1:


[to be completed]


[Supplement to Annex 2:


[to be completed]


Supplement to Annex 3:


[to be completed]


Supplement to Annex 4:


[to be completed]


Supplement to Annex 5:


[to be completed]


Supplement to Annex 6:


[to be completed]


Supplement to Annex 7:


[to be completed]


Supplement to Annex 8:


[to be completed]


 




    	Exhibit A-3



    	 



    

 


ANNEX 1

to Security Agreement


 


CERTAIN GRANTOR
INFORMATION


 


	Grantor	 	Legal

    Name	 	Type

of

    Org.	 	Jurisdiction

of Org.	 	Organization ID

Number

(if applicable)	 	Mailing Address	 	Chief

    Executive

    Office	 	Other Places of

Business and

Collateral Locations	 	Former

Names

(both legal

names and

d/b/as)	 	Former

    Chief

    Executive

    Offices or

    Places of

    Business	 
	Navidea Biopharmaceuticals, Inc.	 	Same	 	Corp.	 	Delaware	 	2159135	 	5600 Blazer Parkway, Suite 200, Dublin, OH 43017	 	Same as mailing address	 	Reliable

        1945 Walton Road

        St. Louis, MO

         

        OsoBio

        4401 Alexander Blvd NE

        Albuquerque, NM

         

        Cardinal NDC

        1950 Bentley Court, Suite
        300

        Glendale Heights, IL

         

        Praxis

        7650 Caterpillar Court
        SW, Ste. D

        Grand Rapids, MI

         
	 	Neoprobe Corporation	 	425 Metro Place North,
        Suite 300

        Dublin, OH 43017

         

        10 New England Business
        Center, Andover, MA 01810
	 
	Macrophage Therapeutics, Inc.	 	Same	 	Corp.	 	Delaware	 	5680660	 	5600 Blazer Parkway, Suite 200, Dublin, OH 43017	 	Same as mailing address	 	None

         
	 	None	 	None	 


 




    	Annex 1-1



    	 



    

 


ANNEX 2

to Security Agreement


 


PLEDGED SHARES


 


1.          Pledged
LLC Interests. Interests in each limited liability company as follows:


 


N/A


 


2.          Pledged
Partnership Interests. Interests in each general partnership, limited partnership, limited liability partnership or other partnership
as follows:


 


N/A


 


3.          Pledged
Stock. Interests in any entity represented by certificates as follows:


 


	Grantor	 	Issuer	 	Certificate

    No.	 	Certificate

    Date	 	No. and Class 

    of Pledged Shares;
 Par Value	 	Pledged Units’

    Percentage of
 all Outstanding
 Units	 
	Navidea Biopharmaceuticals, Inc.	 	Macrophage Therapeutics, Inc.	 	C-001	 	Feb. 26, 2015	 	298,500 common (par value $0.001)	 	 	99	%
	Navidea Biopharmaceuticals, Inc.	 	Navidea Biopharmaceuticals Ltd.	 	5	 	Apr. 14, 2015	 	65 ordinary shares (par value 1p each)	 	 	65	%
	Navidea Biopharmaceuticals, Inc.	 	Cardiosonix, Ltd.	 	A100	 	July 24, 2013	 	213,029.7 common shares (par value 0.1 NIS)	 	 	65	%



 




    	Annex 2-1



    	 



    

 


 


ANNEX 3

to Security Agreement


 


PROMISSORY NOTES


 


None.


 




    	Annex 3-1



    	 



    

 


ANNEX 4

to Security Agreement


 


COPYRIGHTS, COPYRIGHT
REGISTRATIONS AND APPLICATIONS FOR COPYRIGHT REGISTRATIONS


 


	Obligor Owner	 	Title of Work	 	Registration Number (if
 registered)	 	Date of Issuance (if
 Registered) or
 Application Date (if
 applied for only)
	Navidea Biopharmaceuticals Inc.	 	“Neoprobe Corporation OneMedPlace Finance Forum San Francisco, CA January 2010.” 
Registration #: TX0007391587	 	TX0007391587	 	2011-07-01
	Navidea Biopharmaceuticals Inc.	 	“Neoprobe Corporation Product Pipeline — Oncology Diagnostic Drugs.” 
Registration #: TX0007400138	 	TX0007400138	 	2011-07-05



 




    	Annex 4-1



    	 



    

 


ANNEX 5

to Security Agreement


 


PATENTS AND PATENT
APPLICATIONS


 


	Owner	 	Patent Description/Title	 	Jurisdiction	 	Patent Number (if

    issued)/Application

    Number (if applied

    for only)	 	Issuance Date

    (if

    issued)/Filing

    Date (if

    applied for

    only)
	Navidea Biopharmaceuticals, Inc.	 	“Macromolecular
        Carrier for Drug and Diagnostic Agent Delivery”

        (Lymphoseek - Composition)
	 	US	 	6,409,990	 	6/25/2002
	Navidea Biopharmaceuticals, Inc.	 	“Macromolecular
        Carrier for Drug and Diagnostic Agent Delivery”

        (Lymphoseek - Composition)
	 	Europe [France, Germany,
        Netherlands, Italy, Spain Sweden, GB-UK] 
	 	EP1178838B1	 	9/29/04
	Navidea Biopharmaceuticals, Inc.	 	“Macromolecular
        Carrier for Drug and Diagnostic Agent Delivery”

        (Lymphoseek - Composition)
	 	JP	 	4056701	 	3/5/2008
	Navidea Biopharmaceuticals, Inc.	 	“Compositions for
        radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	US	 	8,545,808

         
	 	10/1/2013
	Navidea Biopharmaceuticals, Inc.	 	“Compositions for
        radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	US	 	14/039,648 (Pending)

         
	 	9/27/2013
	Navidea Biopharmaceuticals, Inc.	 	“Compositions for
        radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	EP	 	EP10736135.4 (Pending)	 	1/28/2010
	Navidea Biopharmaceuticals, Inc.	 	“Compositions for
        radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	AU	 	2010208624 (Pending)	 	1/28/2010
	Navidea Biopharmaceuticals, Inc.	 	“Compositions for
        radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	CA	 	2,750,230 (Pending)

         
	 	1/28/2010


 




    	Annex 5-1



    	 



    

 


	Navidea Biopharmaceuticals, Inc.	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	JP	 	
        2011-547973 (Pending)

         
	 	1/28/2010
	Navidea Biopharmaceuticals, Inc.	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	KR	 	2011-7020202 (Pending)	 	1/28/2010
	Navidea Biopharmaceuticals, Inc./OSU	 	
        "Compositions, Methods and Kits for Diagnosing and Treating
        CD206 Expressing Cell-Related Disorders"

        (Lymphoseek – New Field/Composition)
	 	US	 	14/338,332	 	7/22/2014
	Navidea Biopharmaceuticals, Inc./OSU	 	
        "Compositions, Methods and Kits for Diagnosing and Treating
        CD206 Expressing Cell-Related Disorders"

        (Lymphoseek – New Field/Composition)
	 	PCT	 	PCT/US14/47708	 	7/22/2014
	Navidea Biopharmaceuticals, Inc.	 	
        "Compositions and Methods for Diagnosing and Treating Macrophage
        Related Disorders Using Carbohydrate Based Macromolecular Carrier"

        (Lymphoseek – New Field/Composition)
	 	US	 	62/031,348	 	7/31/2014
	Navidea Biopharmaceuticals, Inc./OSU	 	
        "Compounds and Compositions for Targeting Macrophages and
        Other CD206 High Expressing Cells and Methods of Treating and Diagnosing Using Same"

        (Lymphoseek – New Field/Composition)
	 	US	 	62/106,194	 	1/21/2015
	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	US	 	7,772,256	 	8/10/2010


 




    	Annex 5-2



    	 



    

 


	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	EP	 	08724190.7 (pending)	 	3/5/2008
	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	AR	 	080100905 (pending)	 	3/5/2008
	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	AU	 	2008221668	 	7/28/2011
	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	BR	 	PI0808503-0 (pending)	 	3/5/2008
	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	JP	 	552641/2009 (pending)	 	3/5/2008
	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	CA	 	
        2680157

        (pending)
	 	3/5/2008
	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	CN	 	201210093347.6 (pending)	 	3/31/2012
	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	CN	 	200880014994.5	 	6/13/2012
	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	IN	 	5412/DELNP/200 (pending)	 	3/5/2008
	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	KR	 	2009/7018603 (pending)	 	3/5/2008


 




    	Annex 5-3



    	 



    

 


	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	MX	 	299829	 	6/4/2012
	Navidea Biopharmaceuticals, Inc.	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	RU	 	2472789	 	N/A
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	US	 	8,193,363	 	6/5/2012
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	US	 	8,653,274	 	2/18/2014
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	US	 	
        14/149,563

        (pending)
	 	1/7/2014
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	EP	 	
        09810319.5

        (pending)
	 	8/28/2009
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	EA	 	EA19093	 	1/30/2014
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	AR	 	
        090103323

        (pending)
	 	8/28/2009
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	AU	 	2009286176	 	8/23/2012


 




    	Annex 5-4



    	 



    

 


	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	BR	 	
        PI0917147-9

        (pending)
	 	8/28/2009
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	JP	 	
        5613669

        (pending)
	 	10/29/2014
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	CA	 	
        2735497

        (pending)
	 	8/28/2009
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	CN	 	102197036	 	12/10/2014
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	CN	 	
        201410653507.7

        (pending)
	 	N/A
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	CN	 	
        201410655681.5

        (pending)
	 	N/A
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	IN	 	
        1428/DELNP/2011

        (pending)
	 	8/28/2009
	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	KR	 	
        2011/7004579

        (pending)
	 	8/28/2009


 




    	Annex 5-5



    	 



    

 


	Navidea Biopharmaceuticals, Inc.	 	
        “Compounds Suitable as Precursors to Compounds that are
        Useful for Imaging Amyloid Deposits”

        (NAV4694 – Precursor Substance)
	 	MX	 	303024	 	9/4/2012
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	US	 	8,163,928	 	4/24/2012
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	US	 	8,957,215	 	2/17/2015
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	EP	 	
        7709290.6

        (pending)
	 	1/25/2007
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	AR	 	
        70100305

        (pending)
	 	1/24/2007
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	AU	 	
        2007207904

         
	 	1/25/2007
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	BR	 	
        PI0707283

        (pending)
	 	1/25/2007
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	JP	 	5289061	 	1/25/2007
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	CN	 	101410393	 	1/25/2012
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	IN	 	
        6133/DELNP/2008

        (pending)
	 	1/25/2007
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	KR	 	10-1406248	 	6/19/2014
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	RU	 	2008130695	 	1/25/2007
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	MX	 	2008/009396	 	1/25/2007
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl substituted benzoxazoles”

        (AZD2995)
	 	US	 	7,670,591	 	3/2/2010
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl substituted benzoxazoles”

        (AZD2995)
	 	EP	 	
        7748254.5

        (pending)
	 	6/18/2007
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl substituted benzoxazoles”

        (AZD2995)
	 	CN	 	200780030807.8	 	6/18/2007


 




    	Annex 5-6



    	 



    

 


	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl substituted benzoxazoles”

        (AZD2995)
	 	IN	 	
        10035/DELNP/2008

        (pending)
	 	6/18/2007
	Navidea Biopharmaceuticals, Inc.	 	
        “Heteroaryl substituted benzoxazoles”

        (AZD2995)
	 	JP	 	5548842	 	6/18/2007


 




    	Annex 5-7



    	 



    

 


ANNEX 6

to Security Agreement


 


TRADE NAMES,
TRADEMARKS, SERVICES MARKS, TRADEMARK AND SERVICE MARK REGISTRATIONS AND APPLICATIONS FOR TRADEMARK AND SERVICE MARK REGISTRATIONS


  


	Owner	 	Trademark	 	Jurisdiction	 	Registration

Number (if

registered)/Serial

Number (if 

applied for only)	 	Registration

Date (if

registered)/

Filing Date (if

applied for

only)
	Navidea Biopharmaceuticals, Inc.	 	
        “LYMPHOSEEK"

        (Standard Characters)
	 	US	 	3,163,525	 	10/24/2006
	Navidea Biopharmaceuticals, Inc.	 	
        “LYMPHOSEEK"

        (Standard Characters)
	 	CA	 	1647184	 	10/9/2013
	Navidea Biopharmaceuticals, Inc.	 	
        “LYMPHOSEEK"

        (Standard Characters)
	 	EP	 	12,204,202	 	3/5/2014
	Navidea Biopharmaceuticals, Inc.	 	
        “LYMPHOSEEK"

        (Standard Characters)
	 	JP	 	5,649,575	 	2/14/2014
	Navidea Biopharmaceuticals, Inc.	 	
        “LYMPHOSEEK"

        (Standard Characters)
	 	CN	 	13988394	 	1/27/2014
	Navidea Biopharmaceuticals, Inc.	 	
        "LYMPHOSEEK"

        (Logo)
	 	US	 	86/055,675	 	9/4/2013
	Navidea Biopharmaceuticals, Inc.	 	
        "NAVIDEA"

        (Standard Characters)
	 	US	 	4,514,173	 	4/15/2014
	Navidea Biopharmaceuticals, Inc.	 	
        "NAVIDEA"

        (Standard Characters)
	 	CA	 	1647179	 	10/9/2013
	Navidea Biopharmaceuticals, Inc.	 	
        "NAVIDEA"

        (Standard Characters)
	 	EP	 	122,041,786	 	3/6/2014
	Navidea Biopharmaceuticals, Inc.	 	
        "NAVIDEA"

        (Standard Characters)
	 	JP	 	5,652,414	 	2/28/2014
	Navidea Biopharmaceuticals, Inc.	 	
        "NAVIDEA"

        (Standard Characters)
	 	CN	 	14109341	 	3/4/2013
	Navidea Biopharmaceuticals, Inc.	 	
        "NAVIDEA BIOPHARMACEUTICALS"

        (Logo)
	 	US	 	4,207,633	 	9/11/2012
	Navidea Biopharmaceuticals, Inc.	 	
        "MANOCEPT"

        (Standard Characters – Class 5)
	 	US	 	86/287,230	 	5/21/2014
	Navidea Biopharmaceuticals, Inc.	 	
        "MANOCEPT"

        (Standard Characters – Class 42)
	 	US	 	86/287231	 	5/21/2014



 




    	Annex 6-1



    	 



    

 



ANNEX 8

to Security Agreement


 


COMMERCIAL TORT
CLAIMS


 


None.


 




    	Annex 8-1